The global parenteral nutrition market size was estimated at USD 6.7 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 6.0% from 2023 to 2030. Development of technically advanced parenteral nutrition (PN) products with barcode assistance, growing preference for PN over enteral nutrition in patients with COVID-19, shorter hospital stays, along with the reduced risk of infection are some of the factors boosting the product demand, thereby driving the market growth. According to the ASPEN20 Virtual Conference, providing appropriate nutrition to adults with COVID-19 remained a priority for optimizing outcomes. This included overcoming various challenges amid the pandemic, such as a shortage of PN products due to a disrupted supply chain.
Moreover, the increasing prevalence of chronic conditions, majorly cancer & malnutrition, and the rapidly growing geriatric population and natality incidence are high impact-rendering drivers for market growth. Increasing natality is expected to be a major growth driver. Various benefits associated with parenteral nutrition cover easy usage, stimulating stomach blood flow, providing efficient nutrients, and preserving muscle catabolism. An increase in awareness about these benefits is likely to help boost product demand. For instance, educational campaigns pertaining to health awareness, particularly emphasizing nutrition, and various initiatives have been undertaken to promote health & social care.
PN can be given to children and infants suffering from a disease or medical condition, thereby requiring special nutritional management. Specialized Nutrition Europe (SNE) estimated that nearly 300,000 EU children are anticipated to require medical nutrition for their special medical needs in early life stages, which supports growth and development. The study further reveals that about 40% of hospitalized adult patients are malnourished and need medical nutrition to manage the disease-related malnutrition condition, thereby reducing the duration of hospital stay. PN further lowers the infection risk and underdevelopment, thereby promoting its adoption worldwide.
Most of the premature babies suffer from low weight and undeveloped immunity, which puts them at risk. In addition, individuals and healthcare authorities are extensively focusing on limiting mortality due to early birth, thereby driving the use of parenteral lipid emulsions. In 2016, the premature birth rate in the U.S. was about 9.6% and national authorities are working toward reducing it to 8.1%, according to the National Center for Healthcare Statistics. Moreover, a rise in the number of hospitalizations for COVID-19 patients during the pandemic further boosted product adoption in various hospitals, clinics, and Ambulatory Surgical Centers (ASCs).
Changing reimbursement scenarios coupled with other emerging trends to facilitate product adoption are projected to boost market growth in the near future. Various health plans are now available in the U.S. to cope with the problems caused by the COVID-19 pandemic. The immediate implementation of reforms in the Value-based Insurance Design (V-BID) model by the Centers for Medicare & Medicaid Services (CMS) ensures affordable and easy access to critical, clinical services. Thus, the COVID-19 pandemic positively impacted the market and will augment product adoption in the coming years.
Furthermore, the increasing prevalence of chronic conditions, such as cancer, is boosting product usage worldwide. PN helps in the administration of vital nutrients, which helps in maintaining strength, energy, and hydration levels in patients suffering from cancer at all stages, i.e., from diagnosis to recovery. According to the WHO, approximately 8.2 million deaths are recorded each year due to cancer, accounting for 13.0% of deaths worldwide. Moreover, there is expected to be a 70.0% increase in new cases of cancer in the next couple of decades. Thus, the increasing prevalence of cancer is one of the key factors contributing to market growth.
In 2022, the single-dose amino acid solution segment accounted for the largest share of more than 30.9% of the overall revenue. This can be attributed to the increased usage of amino acid solutions, which can be related to a rise in the influx of regulatory-approved solutions. Moreover, newly available amino acid solutions possess fewer side effects, thereby enhancing patient benefits. Aminosyn (by Hospira, Inc.) and Nirmin (by Nirlife Pharma) are a few of the single-dose amino acid solutions available in the market. Formulations of mixed amino acids provide essential and nonessential amino acids.
Hence, the standard component acts as comprehensive parenteral nutrition for overall biological functioning. The parenteral lipid emulsion segment is anticipated to register the fastest CAGR during the forecast period. The development of hybrid parenteral lipid emulsions using mixed lipid emulsions of fish oil and olive oil, the growing adoption of parenteral nutrition over enteral nutrition in COVID-19 patients, shorter hospital stays, and reduced risk of infection are the key factors expected to boost the demand for parenteral lipid emulsions, thereby driving the segment growth.
In 2022, the adult segment held the largest share of 87.0% of the overall revenue.The growing older adult population and an increased prevalence of chronic disorders, such as Alzheimer’s disease, sarcopenia, cancer, and diabetes, among the adult population, support the segment growth. PN products are frequently used by patients when they are unable to consume food and nutrients naturally. The segment is also anticipated to register the fastest growth rate during the forecast period due to the increased product adoption by pregnant women as they need more nutrients to provide adequate nutrition to the developing fetus, which includes iron, fatty acids, amino acids, and vitamins.
Severe malnutrition in pregnant women is associated with factors, such as intrauterine growth restriction, preterm delivery, congenital malformations, low birth weight, and perinatal mortality. Thus, parenteral nutrition is advisable for pregnant women whose nutritional requirements are not being fulfilled by enteral intake.Moreover, the adoption of fat emulsion as part of total parenteral nutrition is increasing for pregnant women. The pediatric segment is anticipated to witness lucrative growth over the forecast period. This is owing to the rising consumption of parenteral nutrition among preterm neonates in their initial life after birth, due to their intolerance to full enteral nutrition and the benefits of PN that provides a relatively safe means for preventing nutritional deficiency.
Based on indications, the others segment dominated the market with a share of 30.9% in 2022.The others indication segment mainly involves Crohn’s disease, cystic fibrosis, pancreatitis, other cancer-related treatment, and other health ailments. Patients undergoing heavy therapies, such as radiation therapy, immunotherapy, and medication, have severe loss of nutrition due to metabolic changes, loss of appetite, and changes in the immune system. Weight loss is the major physical change observed among such patients. Therefore, parenteral nutrition is suggested to such patients to balance their nutrition.
The rising prevalence of various conditions wherein PN can be used for the restoration of nutritional balance is impelling segment growth. However, the dysphagia segment is anticipated to witness the fastest growth rate over the forecast period due to the rising disease prevalence. According to an article published in MDPI in 2022, the prevalence of dysphagia among elderly nursing home residents was around 58.69%, which was evaluated by Standard Swallowing Assessment (SSA). Also, the prevalence of dysphagia in combined community-dwelling elderly was around 30.52%. Furthermore, aspiration pneumonia due to dysphagia is a major complication of this condition, which boosts the need for parenteral nutrition.
In 2022, the institutional sales channel segment dominated the global market with a share of 48.5% of the overall revenue owing to the growing number of private and public healthcare institutions and the increasing chronic disease patient population across the globe. In addition, the purchase decision of parenteral nutrition is influenced by doctors, thereby, impelling the segment growth. The online sales channel segment is expected to witness the fastest growth rate during the forecast period.
This is owing to a shift in a trend toward direct selling to the customer via e-commerce platforms. The preference for online purchase of parenteral nutrition is rising owing to the convenience offered by this sales channel. Although consumed under medical surveillance, these products are intended for long-term nutrition management, resulting in growing sales through e-commerce. Thus, with the penetration of e-commerce, there is a gradual shift toward online purchase of enteral nutrition, thereby offering lucrative market growth opportunities.
North America accounted for the largest share of more than 41.5% of the overall revenue in 2022. Key factors responsible for its largest market share include high research expenditure by private entities & government agencies in the healthcare sector; technologically advanced medical devices; and collaborations among the medical device industry, regulatory authorities, universities, and others. In addition, the growing prevalence of various chronic diseases, such as cancer and malnutrition, and the presence of advanced healthcare facilities, favorable reimbursement policies & regulations in the region have led to a high hospital admission rate.
This supported the high product demand. The Asia Pacific region is anticipated to register the fastest CAGR during the forecast period. The growing prevalence of chronic diseases due to unhealthy eating habits and rising demand for cost-effective treatment of care are some of the factors expected to drive the Asia Pacific regional market growth. Moreover, the growing population, coupled with poverty, and less awareness about nutrition in the region are leading to malnutrition, which is one of the key factors boosting the product demand in the region.
Continuous investments from key operating players for the development of advanced PN solutions have led them to gain a competitive edge in the market, thereby driving market growth. For instance, in January 2020, Fresenius Kabi completed its clinical trial for SmofKabiven. SmofKabiven is their new launch in the range of lipid emulsions. It is made of multiple oils (fish, soybean, & olive oils, and medium-chain triglycerides) along with a separate chamber for amino acids, glucose, and lipids. In addition, companies are actively involved in improving their current product portfolio to sustain their industry position. New drug development by companies and their entry into the untapped markets to expand their reach are also expected to boost industry growth. Some of the key players operating in the global parenteral nutrition market are:
Baxter
Allergan
Actavis Inc.
Otsuka Pharmaceutical Factory, Inc.
Grifols, S.A.
B. Braun Melsungen AG
Vifor Pharma
Fresenius Kabi AG
Sichuan Kelun Pharmaceutical Co., Ltd.
Pfizer Inc. (Hospira Inc.)
Report Attribute |
Details |
Market size value in 2023 |
USD 7.1 billion |
Revenue forecast in 2030 |
USD 10.7 billion |
Growth rate |
CAGR of 6.0% from 2023 to 2030 |
Base year for estimation |
2022 |
Historical data |
2018 - 2021 |
Forecast period |
2023 - 2030 |
Report updated |
July 2023 |
Quantitative units |
Revenue in USD million/billion, and CAGR from 2023 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Nutrient type, stage type, indication, sales channel, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MiddleEast & Africa |
Country scope |
U.S.; Canada; Germany; UK; France; Italy; Spain; Sweden, Denmark, Norway, Thailand, Japan; India; China; Australia; South Korea; Brazil; Mexico; Argentina, South Africa; Saudi Arabia, UAE, Kuwait |
Key companies profiled |
Baxter; Grifols, S.A.; Allergan; Otsuka Pharmaceutical Factory, Inc.; Actavis Inc.; B. Braun Melsungen AG; Fresenius Kabi AG; Vifor Pharma; Sichuan Kelun Pharmaceutical Co., Ltd.; Pfizer Inc. (Hospira Inc.) |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail of customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global parenteral nutrition market report based on nutrient type, stage type, indication, sales channel, and region:
Nutrient Type Outlook (Revenue, USD Million, 2018 - 2030)
Carbohydrates
Parenteral Lipid Emulsion
Single Dose Amino Acid Solution
Trace Elements
Vitamins & Minerals
Stage Type Outlook (Revenue, USD Million, 2018 - 2030)
Adult
Pediatrics
Indication Outlook (Revenue, USD Million, 2018 - 2030)
Alzheimer’s
Nutrition Deficiency
Cancer Care
Diabetes
Chronic Kidney Diseases
Orphan Diseases
Dysphagia
Pain Management
Malabsorption/GI Disorder/Diarrhea
Others
Sales Channel Outlook (Revenue, USD Million, 2018 - 2030)
Online Sales
Retail Sales
Institutional Sales
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
Germany
UK
Italy
Spain
France
Sweden
Denmark
Norway
Asia Pacific
China
India
Japan
Thailand
South Korea
Australia
Latin America
Brazil
Mexico
Argentina
MEA
South Africa
Saudi Arabia
UAE
Kuwait
b. North America dominated the parenteral nutrition market with a share of more than 41.5% in 2022. This is attributable to the high research expenditure by government agencies and private entities in the healthcare sector and the presence of technologically advanced medical devices.
b. Some key players operating in the parenteral nutrition market include Baxter; Grifols, S.A.; Allergan; Otsuka Pharmaceutical Factory, Inc.; Actavis Inc.; B. Braun Melsungen AG; Fresenius Kabi AG; Vifor Pharma; Sichuan Kelun Pharmaceutical Co., Ltd.; and Pfizer, Inc. (Hospira Inc.)
b. Key factors that are driving the parenteral nutrition market growth include the growing presence of a large number of malnourished children, a high natality rate around the globe, increasing premature births, and the rising occurrence of cancer.
b. The global parenteral nutrition market size was estimated at USD 6.7 billion in 2022 and is expected to reach USD 7.1 billion in 2023.
b. The global parenteral nutrition market is expected to grow at a compound annual growth rate of 6.0% from 2022 to 2030 to reach USD 10.7 billion by 2030.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."